Lipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN study [PDF]
, 2015 Fenofibrate lowers triglycerides (TG) and raises high density lipoprotein cholesterol (HDLc) in dyslipidemic individuals. Several studies have shown genetic variability in lipid responses to fenofibrate treatment.
Bertha Hidalgo +10 more
core +2 more sources
Thromboembolic and neurologic sequelae of discontinuation of an antihyperlipidemic drug during ongoing warfarin therapy [PDF]
, 2017 Warfarin and antihyperlipidemics are commonly co-prescribed. Some antihyperlipidemics may inhibit warfarin deactivation via the hepatic cytochrome P450 system.
Bilker, Warren B. +5 more
core +2 more sources
Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review [PDF]
Diabetes & Metabolism JournalHypertriglyceridemia and decreased high-density lipoprotein cholesterol (HDL-C) persist despite statin therapy, contributing to residual atherosclerotic cardiovascular disease (ASCVD) risk.
Chaicharn Deerochanawong +2 more
doaj +1 more source
EBioMedicine, 2016 Neovascular eye diseases including retinopathy of prematurity, diabetic retinopathy and age-related-macular-degeneration are major causes of blindness.
Yan Gong +14 more
doaj +1 more source
Small heterodimer partner-targeting therapy inhibits systemic inflammatory responses through mitochondrial uncoupling protein 2. [PDF]
PLoS ONE, 2013 The orphan nuclear receptor, small heterodimer partner (SHP), appears to play a negative regulatory role in innate immune signaling. Emerging evidence warrants further study on the therapeutic targeting of SHP to suppress excessive and deleterious ...
Chul-Su Yang +8 more
doaj +1 more source
Comparative study of the potential of poly(2-ethyl-2-oxazoline) as carrier in the formulation of amorphous solid dispersions of poorly soluble drugs [PDF]
, 2019 Despite the fact that solid dispersions are gaining momentum, the number of polymers that have been used as a carrier during the past 50 years is rather limited.
Boel, Eline +5 more
core +1 more source
Automation potential of a new, rapid, microscopy based method for screening drug-polymer solubility [PDF]
, 2020 For the pharmaceutical industry, the preformulation screening of the compatibility of drug and polymeric excipients can often be time-consuming because of the use of trial-and-error approaches.
Alhijjaj, Muqdad +4 more
core +1 more source
Uncoupling protein 2: a key player and a potential therapeutic target in vascular diseases [PDF]
, 2017 Uncoupling protein 2 (UCP2) is an inner mitochondrial membrane protein that belongs to the uncoupling protein family and plays an important role in lowering mitochondrial membrane potential and dissipating metabolic energy with prevention of oxidative ...
Forte, Maurizio +6 more
core +2 more sources
Nutrition & Diabetes, 2023 Background Fenofibrate is a hypolipidemic peroxisome proliferator-activated receptor α (PPARα) agonist used clinically to reduce hypercholesterolemia and hypertriglyceridemia. Objective We investigated the effects of fenofibrate on insulin resistance and
Jungu Lee +3 more
doaj +1 more source
Genomic organization, expression analysis, and chromosomal localization of the mouse PEX3 gene encoding a peroxisomal assembly protein [PDF]
, 2000 The peroxin Pex3p has been identified as an integral peroxisomal membrane protein in yeast where pex3 mutants lack peroxisomal remnant structures.
Götte K. +7 more
core +1 more source